Founded in 2013, SeqLL delivers true Single Molecule Sequencing (tSMS) technology to research and healthcare organizations, uniquely positioned to address gaps left by standard sequencing technologies in RNA transcriptome analysis and specialty DNA analysis. The company is advancing application development for early detection of cancer and other diseases alongside technology advancement in rapid screening and sequencing methodologies.
Cyborg Score Rationale
SeqLL operates in the high-potential genomic sequencing market with innovative proprietary technology and government partnerships, but faces significant challenges: minimal revenue (~$330K as of 2026), very small team (3–7 employees), limited commercial traction, and extreme capital constraints despite public listing. The company's published research in prestigious venues (Nature Biotechnology, Cell Reports) and FBI CRADA partnership demonstrate scientific credibility but execution risk remains acute.
Top Insights
SeqLL published early cancer detection research using single-molecule technology in peer-reviewed journal Nature Biotechnology, validating commercial applications in precision diagnostics.
SeqLL entered into a CRADA with the FBI Laboratory Division to advance forensic analysis of bodily fluids using tSMS technology for assay development, expanding addressable market beyond research.
As of May 2026, SeqLL had only 3 employees, indicating extreme capital constraints and pre-commercial stage despite public status.
SeqLL has raised $1.47M in funding across six rounds, suggesting ongoing financing challenges in a capital-intensive biotech space.
Named Competitors
Illumina Sequencing — Market-leading next-generation sequencing platforms and services
PacBio SMRT Sequencing — Long-read sequencing technology for complex genomic analysis
10x Genomics — Single-cell and spatial genomics solutions
BGI Sequencing — Large-scale genomics sequencing services and platforms
Recent Developments
(February 2021) Completed Series A funding round
(August 2021) Listed on NASDAQ via IPO
(September 2022) Published early cancer detection research in Nature Biotechnology
(2025–2026) Entered CRADA with FBI Laboratory Division for forensic sequencing applications
Open the full interactive SeqLL, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.